Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial
伊瓦卡夫托
医学
囊性纤维化
临床试验
儿科
重症监护医学
内科学
囊性纤维化跨膜传导调节器
作者
Claire Wainwright,Susanna A. McColley,Paul McNally,Michael R. Powers,Félix Ratjen,Jonathan H. Rayment,George Retsch‐Bogart,Erica A. Roesch,Neil Ahluwalia,Anna Chin,Chenghao Chu,Mengdi Lu,Prema R. Menon,David Waltz,Tanya G. Weinstock,L. Zelazoski,Jane C. Davies
A 24-week, phase 3, open-label study showed elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was safe and efficacious in children aged 6-11 years with cystic fibrosis (CF) and one or more